JPRN-jRCT2080223021未知1 期
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma
试验速览
- 阶段
- 1 期
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- Histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative treatment is no longer effective
- •- Histologically or cytologically confirmed gastric adenocarcinoma including gastroesophageal junctions that is metastatic, locally advanced or unresectable, and for which standard treatment is no longer
- •effective or tolerable
- •- Eastern Cooperative Oncology Group performance status score 0 or 1
- •- Adequate bone marrow, liver, and renal function according to protocol-defined criteria within the 7 days prior to Day 1 of Cycle 1
- •- Laboratory values within protocol-defined parameters
- •- Agrees to protocol-defined use of effective contraception
- •- Negative urine pregnancy test at screening for women of child bearing potential
排除标准
- •- Has had chemotherapy, radiotherapy, immunotherapy, or treatment with an investigational anticancer agent within 3 weeks (nitrosoureas and mitomycin C within 6 weeks) before the first administration of study drug (localized radiation therapy for palliative purposes and ongoing luteinizing hormone-releasing hormone agonists and antagonists for patients with prostate cancer, bisphosphonates and denosumab are permitted
- •- History or current condition of uncontrolled cardiovascular disease as defined in the protocol
- •- Taking medications known to have a risk of causing QTc prolongation and Torsades de Pointes or known as strong CYP3A inhibitors or inducers
- •- Left ventricular ejection fraction less than (<) 50 percent (%) as assessed by echocardiography performed at screening
- •- Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, ongoing active infection, psychiatric illness, or a risk of gastrointestinal perforation
- •- Woman who is pregnant, breast-feeding, or planning to become pregnant or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
- •- Not recovered from reversible, clinically significant toxicity of prior anticancer therapy
- •- Presence of any medical condition that requires intact wound healing capacity and is expected to endanger participant safety if wound healing capacity would be severely reduced during administration of the investigational agent
- •- Major surgery within 4 weeks before enrollment
- •- Known human immunodeficiency virus infection
- •- Known hepatitis B or C (except hepatocellular carcinoma)
- •- Active, symptomatic, or untreated brain metastasis
研究者
相似试验
已完成
不适用
A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 Monotherapy and Combination Therapy in Subjects with Lymphoid Malignancieson-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, indolent Hodgkin's LymphomaB-cell related malignancy10025319LymphomaNL-OMON39586Gilead Sciences40
已完成
不适用
A Phase 1 Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor, JNJ 38877605 in Subjects With Advanced or Refractory Solid Tumors.Advanced or Refractory Solid Tumorsavailable therapiesno longer likely to benefit from approved10027655NL-OMON31546Johnson & Johnson Pharmaceutical33
尚未招募
不适用
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursNL-OMON51802DeuterOncology NV15
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80